1. Langley, R. G. B., Krueger, G. G., & Griffiths, C. E. M. (2005). Psoriasis: Epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases, 64(suppl 2), ii18–ii23.
2. Perera, G. K., Di Meglio, P., Frank, O., & Nestle, F. O. (2012). Psoriasis. Annual Review of Pathology: Mechanisms of Disease, 7, 385–422.
3. Ortonne, J. P., & Prinz, J. C. (2004). Alefacept: A novel and selective biologic agent for the treatment of chronic plaque psoriasis. The European Journal of Dermatology, 14, 41–45.
4. Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., et al. (2014). Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 70(5), 871–881.
5. Tan, X., Feldman, S. R., & Balkrishnan, R. (2012). Quality of life issues and measurement in patients with psoriasis. Psoriasis: Targets and Therapy, 2(1), 13–23.